Amicus Therapeutics Inc.

12.18+1.24+11.33%Vol 6.32M1Y Perf 8.75%
Aug 5th, 2022 16:00 DELAYED
BID11.81 ASK12.50
Open10.73 Previous Close10.94
Pre-Market- After-Market11.70
 - -  -0.48 -3.94%
Target Price
15.14 
Analyst Rating
Strong Buy 1.29
Potential %
24.30 
Finscreener Ranking
     41.81
Insiders Trans % 3/6/12 mo.
-100/-100/-78 
Value Ranking
     38.68
Insiders Value % 3/6/12 mo.
-100/-100/-98 
Growth Ranking
     38.44
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-98 
Income Ranking
 —    -
Price Range Ratio 52W %
93.30 
Earnings Rating
Sell
Market Cap3.41B 
Earnings Date
4th Aug 2022
Alpha0.00 Standard Deviation0.15
Beta1.07 

Today's Price Range

10.6412.69

52W Range

5.9112.63

5 Year PE Ratio Range

-8.00-7.90

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
22.29%
1 Month
8.85%
3 Months
94.26%
6 Months
35.03%
1 Year
8.75%
3 Years
2.27%
5 Years
-7.94%
10 Years
150.10%

TickerPriceChg.Chg.%
FOLD12.181.240011.33
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
ProfitabilityValueIndustryS&P 500US Markets
88.80
-71.20
-69.30
-399.40
-90.94
RevenueValueIndustryS&P 500US Markets
240.41M
0.86
35.05
85.92
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.23-0.218.70
Q01 2022-0.24-0.30-25.00
Q04 2021-0.14-0.29-107.14
Q03 2021-0.18-0.19-5.56
Q02 2021-0.21-0.199.52
Q01 2021-0.23-0.25-8.70
Q04 2020-0.24-0.27-12.50
Q03 2020-0.20-0.22-10.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.23-4.55Negative
9/2022 QR-0.19-5.56Negative
12/2022 FY-0.89-7.23Negative
12/2023 FY-0.17-6.25Negative
Next Report Date-
Estimated EPS Next Report-0.23
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume6.32M
Shares Outstanding280.16K
Shares Float278.58M
Trades Count50.81K
Dollar Volume75.46M
Avg. Volume3.43M
Avg. Weekly Volume3.53M
Avg. Monthly Volume3.08M
Avg. Quarterly Volume3.69M

Amicus Therapeutics Inc. (NASDAQ: FOLD) stock closed at 12.18 per share at the end of the most recent trading day (a 11.33% change compared to the prior day closing price) with a volume of 6.32M shares and market capitalization of 3.41B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 584 people. Amicus Therapeutics Inc. CEO is John F. Crowley.

The one-year performance of Amicus Therapeutics Inc. stock is 8.75%, while year-to-date (YTD) performance is 5.45%. FOLD stock has a five-year performance of -7.94%. Its 52-week range is between 5.91 and 12.63, which gives FOLD stock a 52-week price range ratio of 93.30%

Amicus Therapeutics Inc. currently has a PE ratio of -11.20, a price-to-book (PB) ratio of 12.74, a price-to-sale (PS) ratio of 12.48, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.93%, a ROC of -36.39% and a ROE of -113.58%. The company’s profit margin is -90.94%, its EBITDA margin is -69.30%, and its revenue ttm is $240.41 Million , which makes it $0.86 revenue per share.

Of the last four earnings reports from Amicus Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Amicus Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Amicus Therapeutics Inc. is Strong Buy (1.29), with a target price of $15.14, which is +24.30% compared to the current price. The earnings rating for Amicus Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amicus Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amicus Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.42, ATR14 : 0.69, CCI20 : 192.28, Chaikin Money Flow : 0.08, MACD : 0.21, Money Flow Index : 52.31, ROC : 10.93, RSI : 48.56, STOCH (14,3) : 83.36, STOCH RSI : 1.00, UO : 60.16, Williams %R : -16.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amicus Therapeutics Inc. in the last 12-months were: Bradley L. Campbell (Option Excercise at a value of $553 633), Bradley L. Campbell (Sold 140 200 shares of value $1 479 573 ), Burke W. Whitman (Buy at a value of $47 196), Daphne Quimi (Sold 4 396 shares of value $39 564 ), Ellen S. Rosenberg (Sold 22 245 shares of value $222 745 ), Glenn P. Sblendorio (Option Excercise at a value of $71 850), John F. Crowley (Option Excercise at a value of $1 047 643), John F. Crowley (Sold 600 842 shares of value $6 476 771 ), Margaret G. McGlynn (Option Excercise at a value of $71 850), Margaret G. McGlynn (Sold 15 000 shares of value $104 897 ), Michael G. Raab (Option Excercise at a value of $71 850), Michael G. Raab (Sold 15 000 shares of value $104 891 ), Samantha Prout (Option Excercise at a value of $48 004), Samantha Prout (Sold 9 970 shares of value $114 663 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
7 (87.50 %)
8 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (12.50 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.25
Strong Buy
1.40

Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Currently, the company is focused on treating Fabry Disease with its treatment Galafold and developing additional therapies for Fabry patients. Amicus has also received breakthrough therapy designation that allows it to deploy a therapy for Pompe Disease in late-stage patients.

CEO: John F. Crowley

Telephone: +1 609 662-2000

Address: 1 Cedar Brook Drive, Cranbury 08512, NJ, US

Number of employees: 584

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

64%36%

TipRanks News for FOLD

Thu, 04 Aug 2022 19:25 GMT Amicus (FOLD) Receives a Hold from Needham

- TipRanks. All rights reserved.

Tue, 10 May 2022 04:45 GMT Analysts Are Bullish on Top Healthcare Stocks: Amicus (FOLD), Cerus (CERS)

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 16:25 GMT Amicus (FOLD) Receives a Hold from Berenberg Bank

- TipRanks. All rights reserved.

News

Stocktwits